Connect with us

Technology

Doctivity Health CEO Cathryn Connolley Named Among Becker’s Healthcare’s “170 Women in Health IT to Know” for 2026

Published

on

BLOOMSBURG, Pa., Jun 8, 2026 /PRNewswire/ — Doctivity Health announced today that its Founder and Chief Executive Officer, Cathryn Connolley, MHSA, has been named to Becker’s Healthcare’s prestigious “170 Women in Health IT to Know | 2026” list, recognizing influential leaders who are transforming healthcare through innovation, technology, and measurable organizational impact.

Doctivity Health CEO Cathryn Connolley named to Becker’s Healthcare’s “170 Women in Health IT to Know | 2026”

Published annually by Becker’s Hospital Review, the list honors women whose leadership is helping healthcare organizations improve efficiency, enhance care delivery, and leverage technology to achieve better outcomes.

Connolley founded Doctivity Health in May 2022 and launched the company in just two months. Since then, the Bloomsburg-based healthcare technology company has secured three rounds of seed funding totaling $5 million, established a national client roster, and helped healthcare organizations generate more than $195 million in new revenue and return on investment through data-driven growth strategies.

“This recognition is an incredible honor, but it is also a reflection of the remarkable team we have built at Doctivity and the healthcare organizations that trust us to help them grow,” said Connolley. “Our mission has always been to provide healthcare leaders with the insights and tools they need to strengthen physician relationships, identify opportunities, and improve access to care. We are proud to be demonstrating that innovation in healthcare can deliver measurable results.”

Under Connolley’s leadership, Doctivity has grown from a startup in Columbia County to a nationally recognized healthcare technology company serving healthcare organizations all across the country.

Doctivity’s platform combines healthcare market intelligence, physician relationship management, and advanced analytics to help healthcare organizations identify growth opportunities, strengthen provider engagement, reduce referral leakage, and improve provider productivity.

The Becker’s recognition highlights Connolley’s extensive healthcare leadership experience. Prior to founding Doctivity Health, she spent 14 years at Geisinger, ultimately serving as Vice President of System Business Development, Marketing Strategy and Operations. She is also an adjunct instructor at Marywood University and serves as a member of the President’s Strategic Counsel at Elizabethtown College.

“Cathy’s foresight has been instrumental in establishing Doctivity as a premier, high-growth healthcare technology firm in Pennsylvania,” remarked Glenn Steele Jr., M.D., Ph.D. Dr. Steele, who led Geisinger Health System as President and CEO from 2001 to 2015, added, “This honor is especially significant because it highlights her dedication to providing healthcare entities with practical solutions that yield quantifiable results.”

According to Becker’s Healthcare, the women recognized on the 2026 list are “harnessing the full power of health IT to drive change that is meaningful and measurable” and are helping healthcare become smarter, more equitable, and more effective.

Headquartered in Bloomsburg, Doctivity Health continues to expand its national footprint while maintaining its roots in Northeastern Pennsylvania. The company recently announced new artificial intelligence initiatives and continues to invest in local talent as it scales its operations.

About Doctivity Health

Doctivity Health is a healthcare technology company that helps healthcare organizations accelerate growth through physician relationship management, healthcare market intelligence, provider productivity analytics, and artificial intelligence. The company’s platform empowers health systems, specialty groups, children’s hospitals, and healthcare organizations to identify opportunities, strengthen provider relationships, and demonstrate measurable return on investment. Doctivity Health is headquartered in Bloomsburg, Pennsylvania.

Media Contact: Dan Carr
Dan@doctivityhealth.com
(843) 441-0760

View original content to download multimedia:https://www.prnewswire.com/news-releases/doctivity-health-ceo-cathryn-connolley-named-among-beckers-healthcares-170-women-in-health-it-to-know-for-2026-302794262.html

SOURCE Doctivity Health

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Takeads launches Zyntent: an AI revenue layer that puts shoppable products in front of users while they’re still deciding

Published

on

By

DUBAI, UAE, July 31, 2026 /PRNewswire/ — Takeads, an adtech company experienced in affiliate and monetization infrastructure, announced the public beta launch of Zyntent, an intent-based monetization platform built to modernize how affiliate and content publishers earn from commercial intent. Built on a live network of more than 55,000 merchants, Zyntent adds a native, intent-matched revenue layer to affiliate and content publishers — and to AI-powered products — running alongside existing affiliate and display revenue rather than replacing it.

Affiliate monetization has run on largely the same mechanism for two decades: an editor manually links a specific product, and only that link earns revenue. Everything else on a page typically earns nothing at all, even on sites with an active affiliate program.

Zyntent is built to close that gap directly. A single API call sends Zyntent a reader’s query or content context. Zyntent determines whether the query carries commercial intent, matches it against a live network of more than 55,000 merchants, and returns a native contextual recommendation — a card, inline suggestion, or search result — in under 50 milliseconds. There is no redirect, no banner, and no pop-up; if no relevant match exists, no placement renders at all.

For affiliate and comparison publishers, that means adding a native, intent-matched recommendation to content, on-site search results, and reader questions that a hand-placed affiliate link never covered — without touching the links and placements that already convert.

“Affiliate monetization has always earned on the one link an editor placed by hand — everything else a reader is asking or comparing on the page has been left on the table. We built Zyntent to close that gap without touching the affiliate and display revenue that already works, so publishers don’t have to choose between the two,” said Kyrylo Kravchenko, Product Lead at Zyntent.

Zyntent is available now in open beta. There is no setup fee; Zyntent operates on a revenue-share model. Documentation and a live sandbox are available as well.

About Zyntent

Zyntent is an intent-based monetization platform that helps affiliate and content publishers turn commercial questions, searches, and conversations into native recommendations, running alongside existing affiliate and advertising programs rather than replacing them. Zyntent is built by Takeads, operating a live network of more than 55,000 merchants.

Contact email: partners@zyntent.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/takeads-launches-zyntent-an-ai-revenue-layer-that-puts-shoppable-products-in-front-of-users-while-theyre-still-deciding-302840226.html

SOURCE Takeads

Continue Reading

Technology

Bidbus Raises $15 Million Series A to Scale Its Live Dealer Auction Marketplace

Published

on

By

Funding will support market expansion, product development, dealer network growth and technology-enabled marketplace operations

IRVINE, Calif., July 31, 2026 /PRNewswire/ — Bidbus, the online automotive marketplace that enables licensed dealers to compete in real time for vehicles directly from consumers, today announced $15 million in Series A funding. The round was led by Ibex Investors, with participation from Mucker Capital, Data Point Capital, FJ Labs, Motley Fool Ventures, Walter Ventures and existing investors.

Bidbus is building the transaction infrastructure for a more transparent and competitive vehicle-selling market. Through its live auction platform, consumers can complete a guided virtual vehicle inspection, set an expected price and receive competing bids from licensed dealerships, rather than relying on a single trade-in or instant-buy offer.

Since launch, Bidbus has served more than 10,000 vehicle sellers and reached approximately $300 million in annualized gross merchandise value. Over the past year, the company has grown sevenfold while expanding its dealer network and establishing operations across California and Texas.

Approximately 39 million used vehicles are sold in the United States each year, yet the process through which consumers sell vehicles and dealerships source inventory remains fragmented and inefficient. Sellers often receive limited visibility into actual dealer demand, while dealerships rely on costly and inconsistent acquisition channels. At the same time, dealers increasingly need access to locally sourced vehicles that match their specific inventory needs.

“Consumers should not have to visit multiple dealerships or negotiate against a single buyer to understand what their car is worth,” said Duke Yan, co-founder and CEO of Bidbus. “We built Bidbus to create a transparent marketplace where qualified dealers compete for every vehicle. This funding allows us to expand that marketplace while building the technology, operating systems and team required to scale.”

Expanding Technology, Operations and Market Coverage

The new capital will be used to expand Bidbus into additional metropolitan markets, grow its dealer network and strengthen its product, engineering and marketplace operations teams.

Bidbus will also continue investing in technology that improves virtual vehicle evaluation, auction performance and operational efficiency. This includes AI-powered seller communication, dealer recommendation tools and internal workflow automation

As Bidbus enters its next phase of growth, the company is transitioning from a founder-led operating model toward a more scalable system of functional ownership, repeatable processes and technology-enabled execution.

“Our next chapter is not simply about adding more markets or more people,” Yan said. “It is about building a marketplace and operating system that can compound—where better technology, stronger dealer participation and more efficient operations reinforce one another as we scale.”

About Bidbus

Bidbus is an online automotive marketplace that connects individual vehicle sellers with licensed automobile dealerships through a live auction platform. The company develops technology for virtual vehicle inspections, condition reporting, auction management, dealer bidding, transaction processing and marketplace operations, helping consumers access competitive dealer offers while giving dealerships a more efficient source of locally available inventory.

Bidbus is headquartered in Irvine, California, and currently operates across major markets in California and Texas. Learn more at www.bidbus.com.

Media Contact
Alex Weinberg
Chief Marketing Officer
Press@Bidbus.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bidbus-raises-15-million-series-a-to-scale-its-live-dealer-auction-marketplace-302839840.html

SOURCE Bidbus

Continue Reading

Technology

Nabsys and Indiana University Collaborate to Advance Electronic Genome Mapping Applications in Hematologic Malignancies

Published

on

By

Multi-year research collaboration will focus initially on AML and MDS while advancing Electronic Genome Mapping for broader hematologic research applications

PROVIDENCE, R.I., July 31, 2026 /PRNewswire/ — Nabsys 2.0, LLC (“Nabsys”), a pioneer in electronic genome mapping (EGM) technology, today announced a multi-year research collaboration with the Indiana University School of Medicine to develop and evaluate Electronic Genome Mapping applications for hematologic malignancies. As part of the collaboration, Kevin T.A. Booth, Ph.D., FACMG, Assistant Professor, Department of Medical and Molecular Genetics, Indiana University School of Medicine, and Clinical Laboratory Director, Indiana University Genetic Testing Laboratories, will evaluate the OhmX™ Platform to support the development and assessment of Electronic Genome Mapping applications, initially focused on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with the potential to extend to additional hematologic malignancies and constitutional disorders over time.

Structural variation plays a central role in many hematologic malignancies. Currently, multiple complementary technologies are required to fully characterize genomic abnormalities. Fluorescence in situ hybridization (FISH) interrogates a limited number of genomic regions, while conventional karyotyping provides a genome-wide view of structural information at relatively low resolution. Through this collaboration, Indiana University and Nabsys will evaluate the use of EGM as a complementary approach for detecting structural variation and determine how it may enhance existing cytogenetic research workflows.

The OhmX™ Platform uses proprietary electronic detection to analyze ultra-long DNA molecules. By replacing complex and expensive optical systems with precision electronics, EGM enables a compact, cost-effective platform capable of delivering high-resolution structural variant and copy number analysis. This fundamentally different approach supports Nabsys’ vision of bringing single-molecule insights to every laboratory in the world by making advanced genome analysis more accessible to researchers.

“Indiana University has long been recognized for excellence in cytogenetics, molecular genetics, and genomic medicine, making it an outstanding collaborator as we continue advancing Electronic Genome Mapping for hematologic malignancy research,” said Barrett Bready, M.D., Founder and CEO of Nabsys. “This collaboration builds on our growing body of work with leading academic laboratories and represents another important step toward developing research applications that address longstanding challenges in structural variant analysis. Dr. Booth and the Indiana University team bring valuable expertise that will help shape the future development of EGM.”

“Structural variation remains one of the most important yet technically challenging aspects of cancer genomics,” said Dr. Booth. “I’m excited to work with the Nabsys team to evaluate Electronic Genome Mapping in AML and MDS and determine where it can complement existing cytogenetic approaches. Every new technology offers an opportunity to see the genome in a different way. This collaboration has the potential to provide new insights into complex genomic abnormalities and advance how we study and understand structural variation.”

Nabsys will also participate in the Cancer Genomics Consortium (CGC) Annual Meeting, taking place August 1–5, 2026, in Houston, Texas, where the Company will present new research highlighting recent progress in Electronic Genome Mapping for hematologic malignancies. Through an oral presentation and three scientific posters, Nabsys will showcase EGM applications for structural variant and copy number analysis, demonstrating the platform’s ability to provide integrated, genome-wide genomic insights that complement existing cytogenetic approaches.

Nabsys’ OhmX™ Platform is a research-use-only EGM technology that is commercially available to laboratories worldwide.

About Kevin T.A. Booth, Ph.D., FACMG

Kevin T.A. Booth, Ph.D., FACMG, is an Assistant Professor in the Department of Medical and Molecular Genetics and Clinical Laboratory Director at the Indiana University School of Medicine. His work focuses on clinical cytogenetics, constitutional genetics, cancer genomics, and the evaluation and implementation of emerging genomic technologies. Dr. Booth is actively involved in advancing cytogenetic methodologies and developing, evaluating, and applying new genomic tools to improve genomic research, laboratory diagnostics, and our understanding of human disease.

About Nabsys

Nabsys is advancing genomics with a clear focus on accessibility and innovation through its proprietary electronic genome mapping (EGM) technology. Implemented on the OhmX™ Platform, EGM integrates precision electronics, nanofluidics, and computational biology to deliver high-resolution insight into genome structure. This approach expands what’s possible in cytogenetics, molecular genetics, and cell and gene therapy research, while providing comprehensive structural variation analysis to laboratories of all sizes.

The company was founded in 2005 and is based in Providence, Rhode Island. For more information, visit www.nabsys.com.

Media Contact
David Rosen
Argot Partners
nabsys@argotpartners.com
646-461-6387

View original content to download multimedia:https://www.prnewswire.com/news-releases/nabsys-and-indiana-university-collaborate-to-advance-electronic-genome-mapping-applications-in-hematologic-malignancies-302840233.html

SOURCE Nabsys

Continue Reading

Trending